BACKGROUND: The contribution of occupational exposures to chronic obstructive pulmonary disease (COPD) and, in particular, their potential interaction with cigarette smoking remains underappreciated. METHODS: Data from the FLOW study of 1202 subjects with COPD (of which 742 had disease classified as stage II or above by Global Obstructive Lung Disease (GOLD) criteria) and 302 referent subjects matched by age, sex and race recruited from a large managed care organisation were analysed. Occupational exposures were assessed using two methods: self-reported exposure to vapours, gas, dust or fumes on the longest held job (VGDF) and a job exposure matrix (JEM) for probability of exposure based on occupation. Multivariate analysis was used to control for age, sex, race and smoking history. The odds ratio (OR) and adjusted population attributable fraction (PAF) associated with occupational exposure were calculated. RESULTS: VGDF exposure was associated with an increased risk of COPD (OR 2.11; 95% CI 1.59 to 2.82) and a PAF of 31% (95% CI 22% to 39%). The risk associated with high probability of workplace exposure by JEM was similar (OR 2.27; 95% CI 1.46 to 3.52), although the PAF was lower (13%; 95% CI 8% to 18%). These estimates were not substantively different when the analysis was limited to COPD GOLD stage II or above. Joint exposure to both smoking and occupational factors markedly increased the risk of COPD (OR 14.1; 95% CI 9.33 to 21.2). CONCLUSIONS: Workplace exposures are strongly associated with an increased risk of COPD. On a population level, prevention of both smoking and occupational exposure, and especially both together, is needed to prevent the global burden of disease.
BACKGROUND: The contribution of occupational exposures to chronic obstructive pulmonary disease (COPD) and, in particular, their potential interaction with cigarette smoking remains underappreciated. METHODS: Data from the FLOW study of 1202 subjects with COPD (of which 742 had disease classified as stage II or above by Global Obstructive Lung Disease (GOLD) criteria) and 302 referent subjects matched by age, sex and race recruited from a large managed care organisation were analysed. Occupational exposures were assessed using two methods: self-reported exposure to vapours, gas, dust or fumes on the longest held job (VGDF) and a job exposure matrix (JEM) for probability of exposure based on occupation. Multivariate analysis was used to control for age, sex, race and smoking history. The odds ratio (OR) and adjusted population attributable fraction (PAF) associated with occupational exposure were calculated. RESULTS: VGDF exposure was associated with an increased risk of COPD (OR 2.11; 95% CI 1.59 to 2.82) and a PAF of 31% (95% CI 22% to 39%). The risk associated with high probability of workplace exposure by JEM was similar (OR 2.27; 95% CI 1.46 to 3.52), although the PAF was lower (13%; 95% CI 8% to 18%). These estimates were not substantively different when the analysis was limited to COPD GOLD stage II or above. Joint exposure to both smoking and occupational factors markedly increased the risk of COPD (OR 14.1; 95% CI 9.33 to 21.2). CONCLUSIONS: Workplace exposures are strongly associated with an increased risk of COPD. On a population level, prevention of both smoking and occupational exposure, and especially both together, is needed to prevent the global burden of disease.
Authors: A Sonia Buist; Mary Ann McBurnie; William M Vollmer; Suzanne Gillespie; Peter Burney; David M Mannino; Ana M B Menezes; Sean D Sullivan; Todd A Lee; Kevin B Weiss; Robert L Jensen; Guy B Marks; Amund Gulsvik; Ewa Nizankowska-Mogilnicka Journal: Lancet Date: 2007-09-01 Impact factor: 79.321
Authors: Geza Benke; Malcolm R Sim; Dean P McKenzie; Ewan Macfarlane; Anthony Del Monaco; Jan L Hoving; Lin Fritschi Journal: Ann Epidemiol Date: 2007-08-24 Impact factor: 3.797
Authors: Sheila Weinmann; William M Vollmer; Victor Breen; Michael Heumann; Eva Hnizdo; Jacqueline Villnave; Brent Doney; Monica Graziani; Mary Ann McBurnie; A Sonia Buist Journal: J Occup Environ Med Date: 2008-05 Impact factor: 2.162
Authors: Philip Harber; Donald P Tashkin; Michael Simmons; Lori Crawford; Eva Hnizdo; John Connett Journal: Am J Respir Crit Care Med Date: 2007-07-12 Impact factor: 21.405
Authors: Mark D Eisner; Paul D Blanc; Edward H Yelin; Patricia P Katz; Gabriela Sanchez; Carlos Iribarren; Theodore A Omachi Journal: Thorax Date: 2010-03 Impact factor: 9.139
Authors: Andreas M Neophytou; Sadie Costello; Sally Picciotto; Elizabeth M Noth; Sa Liu; Liza Lutzker; John R Balmes; Katharine Hammond; Mark R Cullen; Ellen A Eisen Journal: Occup Environ Med Date: 2019-10-14 Impact factor: 4.402
Authors: Mark D Eisner; Carlos Iribarren; Paul D Blanc; Edward H Yelin; Lynn Ackerson; Nancy Byl; Theodore A Omachi; Stephen Sidney; Patricia P Katz Journal: Thorax Date: 2010-11-03 Impact factor: 9.139
Authors: Mark D Eisner; Theodore A Omachi; Patricia P Katz; Edward H Yelin; Carlos Iribarren; Paul D Blanc Journal: Chest Date: 2009-12-29 Impact factor: 9.410
Authors: Brent Doney; Eva Hnizdo; Monica Graziani; Greg Kullman; Cecil Burchfiel; Sherry Baron; Kaori Fujishiro; Paul Enright; John L Hankinson; Karen Hinckley Stukovsky; Christopher J Martin; Kathleen M Donohue; R Graham Barr Journal: COPD Date: 2014-02-25 Impact factor: 2.409
Authors: Neeta Thakur; Paul D Blanc; Laura J Julian; Edward H Yelin; Patricia P Katz; Stephen Sidney; Carlos Iribarren; Mark D Eisner Journal: Int J Chron Obstruct Pulmon Dis Date: 2010-09-07
Authors: Mark D Eisner; Carlos Iribarren; Edward H Yelin; Stephen Sidney; Patricia P Katz; Gabriela Sanchez; Paul D Blanc Journal: Int J Chron Obstruct Pulmon Dis Date: 2009-05-07